Back to Journals » OncoTargets and Therapy » Volume 11

The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER

Authors Tang J, Kong D, Cui Q, Wang K, Zhang D, Liao X, Gong Y, Wu G

Received 24 December 2017

Accepted for publication 29 March 2018

Published 19 June 2018 Volume 2018:11 Pages 3551—3560


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang

Jianing Tang,1 Deguang Kong,2 Qiuxia Cui,1 Kun Wang,3 Dan Zhang,3 Xing Liao,1 Yan Gong,4 Gaosong Wu1

1Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China; 2Department of General Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China; 3Department of Breast and Thyroid Surgery, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 4Department of Biological Repositories, Zhongnan Hospital of Wuhan University, Wuhan, China

Background: Papillary thyroid cancer (PTC) is a common endocrine malignancy with relatively good prognosis. Radioactive iodine (RAI) is considered effective for patients with total or nearly total thyroidectomy, but the beneficial effects of RAI are still controversial.
Materials and methods: To determine whether RAI therapy could improve the survival rates of PTC patients, we conducted a retrospective analysis using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. Disease-specific survival (DSS) was obtained using multivariate Cox proportional hazard regressions.
Results: DSS was improved by RAI ablation in patients with tumor >2 cm, age >45 years and gross extrathyroidal or lymph node metastasis. In a further analysis, RAI therapy did not improve the DSS in patients with tumor <2 cm except those with distant metastasis. For patients with tumor >2 cm, those involving gross extrathyroidal extension, age >45 years or disease in the lymph nodes, DSS was improved after RAI therapy. Patients with distant metastasis always benefited from RAI ablation.
Conclusion: RAI ablation should be recommended to patients with tumor <2 cm and distant metastasis or patients with tumor >2 cm and one of the following risk factors: gross extrathyroidal extension, age >45 years, lymph node and distant metastases.

Keywords: RAI, prognosis, tumor size, metastasis, extension, age

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]